The Zacks Analyst Blog Highlights: Intel, Glaxo, Schwab, Travelers and American Airlines

For Immediate Release

Chicago, IL –March 15, 2017 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Intel (NASDAQ: INTC – Free Report ), Glaxo (NYSE: GSK – Free Report ), Schwab (NYSE: SCHW – Free Report ), Travelers (NYSE: TRV – Free Report ) and American Airlines (NASDAQ: AAL – Free Report ).

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free .

Here are highlights from Tuesday’s Analyst Blog:

Top Research Reports for Wednesday: INTC, SCHW, GSK

Today's Research Daily features new research reports on 16 major stocks, including Intel (NASDAQ: INTC – Free Report ), Glaxo (NYSE:GSK – Free Report ) and Schwab (NYSE: SCHW – Free Report ).

Intel shares have gained only +1.2% since election results were announced on Nov 8, lagging the broader Tech sector (up +8.8%) as well as the red-hot semiconductors space (up +15.6%). Continued weakness in the PC space, greater competition from ARM-based chips and major customers like Google looking for alternatives are some of the headwinds for Intel. But the Zacks analyst sees the Data center business as promising. Further, growing clout in the Internet of Things (IoT) and autonomous driving market are key catalysts. The recently announced Mobileye acquisition will provide competitive edge in the autonomous driving technology market. (You can read the full research report on Intel here >> )

Buy rated Glaxo has outperformed the Zacks Large Cap Pharma sector in the past three months, gaining +9.3% vs a +6.6% increase. The Zacks analyst likes Glaxo’s diversified base and presence in different geographical areas as well as its efforts to develop its pipeline. The performance of new products as well as those acquired from Novartis is also encouraging. These should help support revenues and ease the impact of the loss of Advair sales. However, challenges remain in the form of increasing competition, genericization and pricing pressure, which will continue to impact the company’s performance. (You can read the full research report on Glaxo here >> )

Shares of Schwab have outperformed the Zacks Investment Brokers industry over the last three months, gaining +9% vs +3.7%. The Zacks analyst emphasizes that Schwab is well positioned to benefit from rising rate environment and plans to eliminate fee waivers subsequent to the next rate hike. Also, initiatives to strengthen trading income will support its profitability over the long term, despite the near-term revenue reduction. However, continuous rise in expenses remains a major concern. Significant dependence on fee-based revenue streams also provides cause for apprehension. (You can read the full research report on Schwab here >> )